Is low avidity of human papillomavirus ( HPV ) type 16 antibodies associated with increased risk of low-risk but not high-risk HPV type prevalence?
Association of the low avidity HPV16 antibody "phenotype" with possible susceptibility to infections with other HPV types warrants investigation.
Our results indicate that cetuximab increases the cytotoxic activity of bortezomib in SCC cell lines. Combination therapy of SCC with bortezomib and cetuximab might be less toxic than conventional drug regimens used in the treatment of these tumors.